DRUG RESISTANCE: In vitro preclinical studies identified BRCA2 amplification as a potential mechanism of PARP inhibitor resistance in BRCA2 mutant cancer cell lines.

Web

March 16, 2020

SCIENTIFIC

Amplification of the mutation-carrying BRCA2 allele promotes RAD51 loading and PARP inhibitor resistance in the absence of reversion mutations.

American association for Cancer Research, published October 1, 2019

Abstract

Patients harboring germline Breast Cancer susceptibility genes 1 and 2 (BRCA1/2) mutations are predisposed to developing breast, pancreatic, and ovarian cancers. BRCA2 plays a critical role in homologous recombination DNA repair and deleterious mutations in BRCA2 confer sensitivity to poly(ADP-ribose) polymerase (PARP) inhibition. Recently, the PARP inhibitors olaparib and rucaparib were FDA approved for the treatment of metastatic breast cancer and recurrent ovarian cancer patients with mutations in BRCA1/2. Despite their initial anti-tumor activity, the development of resistance limits the clinical utility of PARP inhibitor therapy. Multiple resistance mechanisms have been described, including reversion mutations that restore the reading frame of the BRCA2 gene. In this study, we generated olaparib and rucaparib resistant BRCA2 mutant Capan1 cell lines. We did not detect secondary reversion mutations in the olaparib or rucaparib resistant clones. Several of the resistant clones had gene duplication and amplification of the mutant BRCA2 allele, with a corresponding increase in expression of a truncated BRCA2 protein. In addition, homologous recombination (HR)-mediated DNA repair was rescued, as evidenced by the restoration of RAD51 foci formation. Using mass spectrometry, we identified Disruptor Of Telomeric silencing 1-Like (DOT1L), as an interacting partner of truncated BRCA2. RNA-interference-mediated knockdown of BRCA2 or DOT1L was sufficient to re-sensitize cells to olaparib. The results demonstrate that independent of a BRCA2 reversion mutation amplification of a mutant-carrying BRCA2 contributes to PARP inhibitor resistance.

https://mct.aacrjournals.org/content/early/2019/10/01/1535-7163.MCT-17-0256